Gilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe<blockquote>吉利德科学表示Kite的Tecartus在欧洲获得治疗复发或难治性套细胞淋巴瘤的有条件上市许可</blockquote>
Gilead Sciences Inc :Kite’S Tecartus™ (Kte-X19) Granted Conditional Marketing Authorization For The